GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Price-to-Operating-Cash-Flow

Karolinska Development AB (Karolinska Development AB) Price-to-Operating-Cash-Flow : (As of May. 17, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Karolinska Development AB Price-to-Operating-Cash-Flow?

As of today (2024-05-17), Karolinska Development AB's share price is $0.2576. Karolinska Development AB's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.01. Hence, Karolinska Development AB's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Karolinska Development AB's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 13 years, Karolinska Development AB's highest Price-to-Operating-Cash-Flow Ratio was 4409.98. The lowest was 10.41. And the median was 35.96.

KDEVF's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 26.395
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Karolinska Development AB's Cash Flow from Operations per share for the three months ended in Mar. 2024 was $-0.00. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.01.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 17.90% per year.

During the past 13 years, Karolinska Development AB's highest 3-Year average Operating Cash Flow per Share Growth Rate was 51.30% per year. The lowest was -60.80% per year. And the median was 13.85% per year.

Karolinska Development AB Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Karolinska Development AB's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB Price-to-Operating-Cash-Flow Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 49.59 - -

Karolinska Development AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Karolinska Development AB's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Karolinska Development AB's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Karolinska Development AB's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karolinska Development AB's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Karolinska Development AB's Price-to-Operating-Cash-Flow falls into.


Karolinska Development AB Price-to-Operating-Cash-Flow Calculation

Karolinska Development AB's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=0.2576/-0.008
=

Karolinska Development AB's Share Price of today is $0.2576.
Karolinska Development AB's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Karolinska Development AB Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Karolinska Development AB (Karolinska Development AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Price-to-Operating-Cash-Flow
Comparable Companies
OSTO:MVIR OSTO:NICA OSTO:INDEX OSTO:IVACC OSTO:IRLAB A OSTO:IMMU OSTO:SANION OSTO:GUARD OSTO:INIT OSTO:KAN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
KDEV:Sweden 2I9:Germany
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Website
https://www.karolinskadevelopment.com
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.